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The impact of hepatitis C virus infection on renal aliograft recipients. A
second generation hepatitis C virus recombinant immunoblot assay
(RIBA) was used to screen stored perioperative serum from 641 renal
allograft recipients. One hundred and nine (17%) were anti-HCV
positive at the time of transplant. RIBA positivity was found to be an
independent predictor of post-transplant liver disease in a logistic
regression model (P < 0.05). Moreover, RIBA positive patients were at
greater risk for infectious events (P = 0.03) and rejection episodes (P =
0.002). The cumulative dose of antilymphoblast globulin administered
as induction therapy was an independent predictor of post-transplant
liver disease in a dose response relationship. Qualitative PCR showed
that 74% of the perioperative RIBA positive patients had detectable
HCV RNA in a current serum sample. Further, quantitative HCV RNA
analysis with a competitive template PCR and HCV strain identification
by restriction fragment length polymorphism demonstrated a large
range of HCV RNA copies/mi of serum and three different HCV strains
(BK, Hutch and HCV-l). Neither quantity of HCV RNA nor strain type
correlated with abnormal transaminases post-transplant. As yet, there
has not been an effect of anti-HCV status on actuarial patient and graft
survival. This study suggests that anti-HCV is not a contraindication to
renal transplantation; however, we would recommend that the pre-
transplant evaluation of the anti-HCV positive patient include a liver
biopsy to properly stage the disease. Close post-transplant follow-up is
required in view of the increased risk for infection and rejection.
The success of renal transplantation as a therapy for end-
stage renal disease has focused attention on factors effecting
long-term patient and graft survival. Although the spectrum of
liver disease following renal transplantation is varied [1—5],
chronic liver disease contributes substantially to late post-
transplant morbidity [6—8]. The development of an immunoas-
say to detect antibody to hepatitis C virus [91 (anti-HCV) and
the subsequent screening of large numbers of kidney recipients
demonstrated that HCV was the causative agent for most cases
of what had previously been referred to as post-transplant
non-A, non-B hepatitis (NANBH) [10, 11]. Whereas numerous
studies have emphasized the importance of hepatitis B virus
infection in the immunosuppressed transplant recipient [6, 12,
13], far less is known about the natural history of HCV infection
in this patient population [11, 14].
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Considering that 10 to 30% of hemodialysis patients in the
United States are anti-HCV positive [17, 18], the pre-transplant
evaluation of these patients and the contribution of HCV
infection to long-term patient outcome are important issues. We
have previously reported that 30% of our transplant recipients
were anti-HCV positive using a first generation anti-HCV
ELISA [191. The aims of the current study were to: (1)
determine the perioperative seroprevalence of anti-HCV in a
large series of renal allograft recipients using second generation
testing; (2) assess the impact of HCV infection on long-term
outcome; and (3) determine which factor(s) were predictive of
post-transplant liver disease in the anti-HCV positive renal
transplant candidate.
Methods
Anti-HCV assay
Stored perioperative serum samples (—70°C) from 641 pa-
tients transplanted at the University of Miami/Jackson Memo-
rial Medical Center between 1979 to 1991 were tested for
anti-HCV using a second generation recombinant immunoblot
assay (RIBA) (Ortho Diagnostics, Raritan, New Jersey, USA).
Assays were performed in duplicate following manufacturer's
instructions. Samples with two or more bands were considered
positive.
Detection of HCV RNA by polymerase chain reaction (PCR)
RNA was extracted and precipitated by adding 100 /.LJ of
serum to 900 l RNAzoI B (Cinna-Biotex Laboratories, Friens-
wood, Texas, USA) [20]. Reverse transcription and subsequent
PCR amplification were performed by the methods described in
the GeneAmp RNA PCR kit (Perkin-Elmer Cetus, Emeryville,
California, USA) using 2 d of RNA solution (2 d equal RNA
from 10 l of serum). The primers used were from the 5'
untranslated region of the HCV genome [21]. The sense primer
was of the sequence 5' -CCC AAC ACT ACT CGG CTA G-3'.
The anti-sense primer was of the sequence 5' -AAC TAC TOT
CTT CAC GCA GAA AGC-3'. For cDNA synthesis, 15 pmol of
the anti-sense primer were used in a 20 j.d reaction. For the
subsequent PCR amplification, 15 pmol of the sense primer
were added along with the remainder of the amplification
components. A 46 cycle amplification procedure at 94°C for 1.5
minutes, 60°C for 2 minutes, and 72°C for 3 minutes, was
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performed. The amplified product was analyzed by gel electro-
phoresis using 3% NuSieve agarose (Rockland, Maine, USA)
and ethidium bromide staining. RNA extraction and PCR
amplification were performed with positive and negative con-
trols.
Generation of competitive substrate for HCV PCR
For quantitation, a competitive template PCR method [22]
was utilized after cDNA synthesis. The competitive template
was developed using a recombinant DNA protocol in which a
recombinant DNA clone of the HCV region utilized for RNA
detection was generated by PCR with primers designed to flank
the amplification region. The sense primer was of the sequence
5' -ATG GAT CCC TCC CCT GTG AGG AAC TA-3'. The
antisense primer was of the sequence 5' -CAA GGA TCC TAT
CAG GCA GTA CCA GTT-3'. The cDNA synthesis and PCR
amplification were performed as described, except the cloning
primers were substituted for the original PCR primers. Each
cloning primer included a BamHI site to facilitate the molecular
cloning protocol. After amplification and preparative agarose
gel electrophoresis, the 256base pair (bp) specific PCR product
was isolated by electroelution (IBI, New Haven, Connecticut,
USA). The purified DNA was then digested with BamHI and
ligated into the BamHI site of the cloning vector pBluescript SK
+ (Stratagene, San Diego, California, USA). Individually trans-
formed bacteria (XL-! blue) were screened for the insert using
PCR. This resulted in the isolation of a recombinant positive
control clone (pHCV-!). To generate the recombinant compet-
itor substrate, pHCV-! was digested with the restriction en-
zymes NcoI and NheI. This resulted in the elimination of the
166 bp of DNA internal to the original PCR primers, including
the HCV specific internal probe sequence. In parallel, the
plasmid PPL-lambda (Pharmacia-LKB, Piscataway, New Jer-
sey, USA) was digested with the restriction enzymes NheI and
BspHl. Both digestion reactions were subjected to preperative
agarose gel electrophoresis, after which the large fragment of
the pHCV-! digestion and the 294 bp fragment of the pL
lambda digestion were isolated by electroelution. The two
purified DNA's were ligated together and transfected into the
bacteria strain XL-l blue. The individual bacterial colonies
were screened using PCR. Clones which demonstrated a PCR
product 128 bp larger than the HCV-RNA PCR product (344 bp
total length) were retained (pHCV-C).
Quantitation of HCV using competitive template PCR
Several parallel cDNA reactions were performed, using 2 l
of the RNA samples (see above). Following cDNA synthesis, 2
d of EcoRI linearized plasmid pHCV-C diluted serially tenfold
were added as substrate along with the remainder of the PCR
components. Initial dilutions ranged from 10—6 to 10—12 of
plasmid (between 4 x !0 copies/id down to 0.4 copies/jsl of
competitor). PCR reactions were run for 46 cycles as described.
The PCR products (10 pl) were visualized using EthBr staining
after separation in a 3% NuSieve agarose gel. After photograph-
ing the gel, each of the experimental and competitor PCR
products was quantitated from the negative using a laser
densitometer (Molecular Dynamics Personal Densitometer,
Sunnyvale, California, USA). The concentration of unknown
HCV RNA substrate was calculated from the reaction in which
the ratio of the HCV PCR product to the known quantity of
competitor PCR product was closest to 1.0. For more accuracy,
six additional cDNA reactions were prepared as twofold dilu-
tions and run as described. The range of dilutions was deter-
mined from the initial tenfold dilution series results. Viral
burden (in copies of virus/pi) was then calculated.
HCV strain identification using PCR restriction fragment
length polymorphism (RFLP) and direct sequencing
A PCR-RFLP assay was designed using known sequences in
the 5' non-coding region of the HCV genome from nine major
strain variants [2!, 23—29]. The cDNA synthesis and PCR
amplification were performed using RNA isolated from serum
as described, except that an anti-sense primer of sequence 5'
-TAG G11 GTC GCC TTC CAC GA-3' was substituted for the
original anti-sense primer in both the cDNA and PCR reactions.
This primer set resulted in a PCR amplification product of 482
base pairs. Following amplification, 10 td of the PCR product
was placed into seven separate tubes containing 1.0 tl of the
appropriate lOx restriction endonuclease buffer and 10 units of
the following enzymes, respectively: Aflill, BspHI, BspAI,
Hinfi, Mbo 1, and Sty 1. The last tube was incubated with no
enzyme as a control. Reactions were incubated for two hours at
37°C, then separated on a 4% NuSieve agarose gel, with
visualization by staining with EthBr. Restriction maps of the
PCR products from the 9 HCV strains with the selected
enzymes listed above could then be created with each strain
predicted to give a unique restriction pattern based on known
sequence variations in this region.
HCV strains identified by PCR-RFLP were confirmed by
directly sequencing the PCR products by the method of Green,
Roopra and Vaudin [30]. The PCR-RFLP primer sets were used
for the cDNA synthesis and PCR application. The same primers
served as the sequencing primers to sequence both strands of
the HCV-PCR product.
Mixed lymphocyte reactions
Peripheral blood mononuclear cells were isolated from the
blood of RIBA positive (N = 10) and RIBA negative (N = 19)
pre-transplant patients using Ficoll Hypaque density gradients
as previously described [31]. Assays were performed in tripli-
cate using 1 x !0 responding cells from the patient mixed with
1 x !0 x-irradiated (1500 rad) stimulating cells obtained from a
2-DR mismatched volunteer. The incorporation of [3H]-thymi-
dine was reported as the number of mean counts per minute.
Post-transplant complications
Chronic hepatitis was defined as a greater than twofold
elevation of the alanineaminotransferase for greater than six
months duration. The histologic diagnosis of chronic hepatitis
was according to standard criteria [32]. Acute rejection was
diagnosed by biopsy or response to appropriate anti-rejection
therapy. Infectious episodes were included only when serious
enough to require hospitalization and antimicrobial therapy.
Statistical analysis
Chi-square test with a Yates correction factor and the Stu-
dent's t-test were used for statistical analysis of the univanate
variables. A multiple logistic analysis was performed using the
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Table 1. Patient characteristics according to post-transplant liver
function
Post-transplant liver function
Normal Abnormal
Variable N = 234 N = 75 P value
Age years 449 11.7 44.2 12.4 NS
Gender male/female 134/100 47/28 NS
Follow-up months 68.7 28.8 78.9 33.7 <0.01
Blood no. unit? 7.2 7.4 10,2 13.6 <0.001
Preoperative LFF'&' 0/232 4/75 (5.3) 0.003
ALG mgc 6692 5882 5861 5927 NS
Infectionsd 33/234 (14) 15/75 (20) NS
Rejections 55/234 (24) 25/75 (34) NS
RIBAC 72/234 (31) 37/75 (51) <0.003
Each value denotes mean SD. Numbers in parenthesis are percent-
ages.
a Preoperative blood transfusionsb Abnormal pretranspiant liver function tests
C Total antilymphoblast globulin administered as induction therapyd Requiring hospitalization and antimicrobial therapy
C Recombinant iinmunoblot assay. Number of positive samples di-
vided by the number tested from a perioperative serum sample
BMDP program with post-transplant liver disease as the depen-
dent variable. Actuarial patient and graft survival were calcu-
lated by the Wilcoxan method. Values are expressed as mean
standard deviation (SD). Statistical probability of less than 0.05
was considered significant.
Results
Seroprevalence of anti-HCV
Stored perioperative samples from 641 patients transplanted
at the University of Miami/Jackson Memorial Medical Center
between 1979 to 1991 were tested for anti-HCV. Of this group,
109 (17%) were RIBA positive. A group of 200 pei-ioperative
RIBA negative recipients who had adequate follow-up data
available and a minimum of six months of graft function were
selected for comparison to the RIBA positive cohort.
Post-transplant liver function
Chronic liver disease developed in 75 (24%) of the 309
patients included in the analysis. There were no differences in
age, gender, infectious episodes, acute rejections or total dose
of induction antilymphoblast globulin (ALG) administered be-
tween the two groups (Table 1). Patients with post-transplant
liver disease had been followed longer and were more likely to
have had abnormal liver function tests pre-transpiant. Further-
more, both the number of pretransplant blood transfusions (P <
0.001) and the number of patients who were RIBA positive at
the time of transplant (P =0.003)were greater in the group that
developed post-transplant liver disease. Application of a logis-
tic regression model to this group confirmed that RIBA positiv-
ity was an independent predictor of post-transplant liver dys-
function (odds ratio = 2.13; P < 0.05). The number of units of
blood transfused only approached significance (odds ratio =
1.02; P 0.06).
Table 2. Univariate analysis of the study population according to
perioperative anti-HCV serostatus
Variable
Anti-HCV
P value
Positive
N = 109
NegativeN = 200
Age years 47 11.3 42.9 12.5 NS
Gender male/female 66/43 115/85 NS
Follow-up months 65.7 28.9 81.3 30.3 <0.001
Blood no. unitsa 9.5 13.4 6.9 5.7 <0.001
Preoperative LFF's" 3/109 (2.7) 1/200 (0.5) NS
ALG mgc
Infections"
6983 6169
24/109 (22)
6451 5750
26/200 (13)
NS
<0.03
Rejections 40/109 (37) 41/200 (20) <0.002
Abnormal LFT 37/109 (34) 38/200 (19) <0.002
Each value denotes mean SD. Numbers in parenthesis are percent-
ages. Anti-HCV detected by recombinant immunoblot assay.
a Preoperative blood transfusionsb Abnormal pretransplant liver function tests
C Total antilymphoblast globulin administered as induction therapy
"Requiring hospitalization and antimicrobial therapy
Chronically abnormal liver function tests post-transplant
Post-transplant outcome according to RIBA status at
transplant
Comparison of the 109 RIBA positive patients to the sero-
negative cohort demonstrated no difference in age, gender,
ALU dosage or number of patients with pretranspiant liver
disease (Table 2). However, the RIBA positive group had a
shorter length of follow-up (65.7 28.9 vs. 81.3 30.3
months), received significantly more units of blood (9.5 13.4
vs. 6.9 5.7;P < 0.001), had a greater number of rejection and
infectious events (37% vs. 20.7% and 22% vs. 12.4%, P =0.002
and P = 0.03, respectively), and had a larger number of patients
develop liver dysfunction post-transplant (34% vs. 18.6%, P =
0.002). Application of a logistic regression model to the RIBA
positive cohort identified only ALG as a predictor of abnormal
liver function (P < 0.05). Furthermore, this effect performed in
a dose-dependent manner. Receiving 250 to 9999 mg of ALG
increased the risk of liver disease (odds ratio P = 2.11; P <
0.05), while receiving greater than 9999 mg further increased the
risk (odds ratio = 4.1; P < 0.05).
Lymphoprolferative assays
Mixed lymphocyte reactions were performed using cells
obtained from RIBA positive and negative ESRD patients being
considered for transplantation. The seven day (3H)-thymidine
uptake in the seronegative cohort was more than two times
greater than the anti-HCV positive group (30,1243 4123 cpm
vs. 12,164 3141 cpm; P = 0.04).
Detection of HCV RNA and strain identification
Of the 109 RIBA positive patients identified, 30 have expired
and 26 have been lost to follow-up or returned to dialysis. Of the
remaining 53, 39 (74%) had detectable levels of HCV RNA in a
fresh serum sample. Among the PCR positive patients, 20(51%)
have always maintained normal biochemical measures of liver
function while 19 (49%) have had chronically abnormal trans-
aminases. Only 1 out of 14 PCR negative patients have had
elevated transaminases during post-transplant follow-up. Fresh
serum from 34 out of 200 perioperative RIBA negative patients
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Table 3. Results of quantitative polymerase chain reaction and HCV
strain identificationa
Post-transpiant liver function
Normal Abnormal PN20 N=19 value
HCV RNA (copies/mi x106) 6.4 1.6 9.0 4.5 NS
Strain
BK (N = 10) 6.5 1.6 (4) 18.5 13.9 (6) NS
Hutch (N = 11) 11.6 4.1 (6) 6.7 2.8 (5) NS
HCV-1 (N = 6) 15.5 9.1 (5) 5.2 (1) NS
HCV-i/BK (N = 1) 8.8 (1) — —
HCV-1/Hutch (N = 1) — 8.8 (1) —
Each value denotes the mean SD. Numbers in parenthesis repre-
sent the number of patients in each group.
a Strain identification by restriction fragment length polymorphism of
PCR product with confirmation by direct sequencing. Strain identifica-
tion in patients with very low viral titers was not possible.
was tested for HCV RNA. This group was matched by age and
number of transfusions with the 39 PCR positive patients
identified from the RIBA positive group. HCV RNA was
detected in 4 out of 34 specimens. Anti-HCV by RIBA was
present in three of these four samples. Three of the four patients
have had chronically abnormal liver enzymes post-transplant,
yet all were RIBA negative with normal LFT's at the time of
transplant.
Quantitative PCR analysis was performed on the 39 samples
from the RIBA positive group which were positive on qualita-
tive testing. As shown in Table 3, patients with normal liver
function had 6.4 1.6 x 106 copies/ml of HCV RNA versus 9.0
4.5 x 106 in the group with liver disease (P = NS).
Strain identification by RFLP testing of the PCR product
demonstrated that HCV strains BK (N = 10), Hutch (N = 11),
and HCV-l (N = 6) were present in our patient population
(Table 3). Two patients were infected with two different strains
of HCV (BKIHCV-l and Hutch/HCV-l). There were no signif-
icant differences in viral copy number between those patients
with or without liver disease within each strain subgroup.
Liver histology
Liver biopsies were performed in 10 of the 19 PCR positive
patients with chronically abnormal liver enzymes at an interval
of 64.8 17 months (range 41 to 92 months) post-transplant.
Histologic changes of chronic persistent hepatitis were present
in four, chronic active hepatitis in five, and cirrhosis in one.
Patient and graft survival
Actuarial patient and graft survival were calculated for the
RIBA positive and negative groups. Patient and graft survival at
five years in the RIBA positive cohort (81% and 63%, respec-
tively) did not differ from the RIBA negative group (80% and
63%, respectively). There have been no deaths attributable to
liver failure.
Discussion
Using a second generation anti-HCV assay, 17% of serum
samples collected from our patients at the time of transplanta-
tion were anti-HCV positive. This is consistent with reports
from other centers in which 6 to 48% of patients were anti-HCV
positive when transplanted [14—16, 33—35]. These findings are
not unexpected, considering the high prevalence of anti-HCV
reported among hemodialysis patients [36—41]. In fact, length of
time on dialysis and number of blood transfusions have been
repeatedly shown to be predictors of anti-HCV positivity in
transplant recipients [14, 33, 42]. Although significant in the
univariate analysis, in our study the number of pretranspiant
blood transfusions only approached significance (P = 0.06) in
the logistic regression model as a predictor of post-transplant
liver dysfunction.
We found RIBA positivity to be an independent predictor of
post-transplant liver disease. Chan, Lok and Cheng [15] re-
ported similar results, although 75% of their anti-HCV positive
patients developed liver dysfunction in contrast to only 34% of
our RIBA positive cohort. We also observed a relationship
between the dosage of ALG administered for induction therapy
and the likelihood that the RIBA positive patient would develop
post-transplant liver disease. Antilymphocyte preparations are
known to predispose to viral reactivation [43], thus our findings
are not surprising and emphasize the need to use these products
with caution in the RIBA positive transplant recipient.
Patients who were seropositive for anti-HCV were more
heavily transfused and were more likely to experience serious
infectious events and acute rejection episodes (Table 2). Prior
studies have suggested that transplant recipients with active
viral replication (that is, cytomegalovirus) are further immuno-
suppressed as a consequence of an interaction between the viral
infection and the host's immune responsiveness [44, 45]. In
mixed lymphocyte cultures, we found that peripheral blood
mononuclear cells isolated from anti-HCV positive ESRD pa-
tients showed less than 50% of the lymphoproliferative activity
of cells obtained from a similar group of anti-HCV negative
patients. Our in vitro findings are interesting and consistent with
the clinical pattern; however, further study is required to
properly elucidate the mechanism whereby HCV infection may
interfere with the host's immune surveillance. Seemingly at
odds with these findings was the nearly twofold increase in
rejection episodes occurring among the anti-HCV positive
patients. This contrasts with the results of Ponz et al [14] who
reported no difference in rejection rates between anti-HCV
positive and negative patients. Although an explanation for our
findings is not readily apparent, several possibilities exist. It is
likely that the amount of immunosuppression the patients were
receiving was markedly reduced following a serious infection,
thus permitting an alloimmune response against the graft to
occur. In fact, 10 out of 24 (4 1%) RIBA positive patients with
infection experienced at least one rejection episode. Alterna-
tively, HCV infection could initiate a process which results in
the up-regulation of MHC class II antigen expression in the
allograft. In this regard, kidney recipients with active CMV
infection have been described who either concomitantly or
shortly thereafter developed acute rejection [46]. In view of
these risks, we suggest that the anti-HCV positive kidney
recipient be closely monitored for infection and allograft dys-
function. Furthermore, because our data link ALG dosage with
post-transplant liver dysfunction, the use of antilymphocyte
preparations in the HCV infected patient with allograft rejection
becomes problematic. If possible, anti-lymphocyte products
should not be used as first-line therapy to treat rejection in these
individuals.
HCV RNA was detected in the serum of 39 out of 53 (74%)
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patients who were RIBA positive when transplanted. Particu-
larly striking was the finding that 20(51%) PCRpositive patients
maintained normal transaminases throughout their post-trans-
plant follow-up. Ponz and colleagues reported the development
of liver disease in two-thirds of the anti-HCV carriers trans-
planted at their center [14]. Thus, between 33 to 51% of the
anti-HCV positive transplant recipients in these two reports
maintained normal LFT's, emphasizing the low sensitivity of
liver transammases to detect active viral replication, a finding
previously noted in hemodialysis patients [47]. We recommend
that every patient with documented HCV infection and abnor-
mal transaminases have a liver biopsy to morphologically
characterize the extent of disease. This approach is supported
by recent data from Rao et al, demonstrating histologic progres-
sion to cirrhosis in serial biopsies obtained from transplant
patients with chronic active hepatitis [48]. Until data are
available describing the liver histology and clinical course in
HCV infected transplant patients with normal transaminases,
recommendations on the timing and/or usefulness of a liver
biopsy in this cohort of patients are impossible.
Analysis of fresh serum from a subset of 34 perioperative
RIBA negative patients identified four with circulating HCV
RNA. Because PCR analysis cannot be reliably performed on
stored perioperative samples, it is impossible to determine with
certainty whether these patients were viremic (and anti-HCV
negative) at the time of transplantation. However, the anti-
HCV seroconversion of 3 out of 4 of these PCR positive
patients in the post-transplant period suggests that HCV infec-
tion was acquired after surgery.
Quantitative PCR analysis of fresh serum from the 39 RIBA
positive and HCV RNA positive patients demonstrated a wide
range of viral copy number to be present (0.0 13 to 88 X 106/ml).
Moreover, there was no correlation between HCV copy num-
ber and biochemical liver function abnormalities. This finding
must be confirmed in a larger number of patients.
It has become apparent from the literature that HCY repre-
sents a variable group of agents. Multiple HCV strains have
been identified worldwide, and comparative sequence analysis
of the published HCV sequences indicates that they can be
broadly subdivided into three basic groups [23]. We detected
HCV strains HCV- 1, BK and Hutch among our patients (Table
3), one of which (BK) was originally reported from Japan [25].
Of interest, two patients were infected with two different strains
of HCV. It will be important to study the clinical consequence
of infection with multiple HCV strains. In our relatively small
series, we were unable to detect any clinical patterns which
would suggest differences in strain virulence. Nevertheless, the
possibility that different HCV agents cause varying clinical
outcomes requires investigation, especially in the immunosup-
pressed transplant recipient. An association between liver
cirrhosis and hepatocellular carcinoma has been reported in
HCV infected Japanese patients [49], and a recent report of
hepatocellular carcinoma developing in a Japanese renal al-
lograft recipient [50] suggests that increased surveillance for
cirrhosis and/or early carcinoma is warranted for the HCV
infected transplant recipient. This may be especially true for
patients infected with strains of HCV originating in Japan (that
is, BK).
Actuarial five year patient and graft survival did not differ
between the anti-HCV positive and anti-HCV negative groups.
This is in agreement with several other published series [11, 16,
36] but appears to differ from data reported by Pereira, et al on
a series of patients in whom transmission of HCV with the
organ was likely to have occurred [51, 52]. In Pereira's study,
the post-transplant course of HCV infection was particularly
aggressive in that all of their patients with liver disease pro-
gressed to chronic hepatitis or subfulminant liver failure.
Clearly, this has not been our own experience, and possible
explanations including variability in strain virulence, viral bur-
den, and differences in immunosuppressive protocols, will
require further study. Furthermore, follow-up of greater then 10
years, including serial liver biopsies, will be necessary to
determine the true impact of HCV infection on long-term
morbidity and mortality.
In summary, recent studies have identified HCV as the
primary caUse of post-transplant NANBH [10, 11]. Our data
suggest that the anti-HCV positive patient is at increased risk
for infection, rejection and post-transplant liver disease. How-
ever, we have not as yet observed a difference in patient and
graft survival, thus we do not consider HCV infection to be a
contraindication to renal transplantation. We would suggest,
however, that the evaluation of the anti-HCV positive trans-
plant candidate should include PCR testing, if available, and
liver biopsy to histologically stage the patient's disease. Al-
though interferon has been shown to be effective therapy for
hepatitis due to HCV infection [53], its role in the treatment of
ESRD patients has not been carefully studied. Pol et al have
reported that anti-HCV antibodies detected at the time of
transplantation are not systematically associated with the de-
velopment of chronic liver disease [11]. However, sufficient
data are not yet available to determine whether the HCV
infected patient with biopsy-proven chronic active hepatitis or
early cirrhosis should be transplanted or remain on dialysis.
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